bazedoxifene has been researched along with osimertinib in 2 studies
| Studies (bazedoxifene) | Trials (bazedoxifene) | Recent Studies (post-2010) (bazedoxifene) | Studies (osimertinib) | Trials (osimertinib) | Recent Studies (post-2010) (osimertinib) |
|---|---|---|---|---|---|
| 307 | 69 | 249 | 1,315 | 134 | 1,282 |
| Protein | Taxonomy | bazedoxifene (IC50) | osimertinib (IC50) |
|---|---|---|---|
| Histone deacetylase 3 | Homo sapiens (human) | 1 | |
| Lysine-specific histone demethylase 1A | Homo sapiens (human) | 3.98 | |
| Epidermal growth factor receptor | Homo sapiens (human) | 0.1858 | |
| Receptor tyrosine-protein kinase erbB-2 | Homo sapiens (human) | 0.0274 | |
| Insulin receptor | Homo sapiens (human) | 0.912 | |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | 3.26 | |
| Receptor tyrosine-protein kinase erbB-3 | Homo sapiens (human) | 0.0268 | |
| von Hippel-Lindau disease tumor suppressor | Homo sapiens (human) | 0.002 | |
| Histone deacetylase 4 | Homo sapiens (human) | 1 | |
| Fatty-acid amide hydrolase 1 | Rattus norvegicus (Norway rat) | 0.0395 | |
| Epidermal growth factor receptor | Mus musculus (house mouse) | 0.081 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 0.57 | |
| Histone deacetylase 1 | Homo sapiens (human) | 1 | |
| Receptor tyrosine-protein kinase erbB-4 | Homo sapiens (human) | 0.033 | |
| Histone deacetylase 7 | Homo sapiens (human) | 1 | |
| Histone deacetylase 2 | Homo sapiens (human) | 1 | |
| Polyamine deacetylase HDAC10 | Homo sapiens (human) | 1 | |
| Histone deacetylase 11 | Homo sapiens (human) | 1 | |
| Histone deacetylase 8 | Homo sapiens (human) | 1 | |
| Histone deacetylase 6 | Homo sapiens (human) | 1 | |
| Histone deacetylase 9 | Homo sapiens (human) | 1 | |
| ALK tyrosine kinase receptor | Homo sapiens (human) | 0.177 | |
| Histone deacetylase 5 | Homo sapiens (human) | 1 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Byun, SY; Choi, I; Jeon, S; Kim, S; Ko, M; Lee, J; Park, S; Shum, D | 1 |
| Huang, Q; Liao, Y; Lin, W; Meng, Y; Wang, N; Wei, X | 1 |
2 other study(ies) available for bazedoxifene and osimertinib
| Article | Year |
|---|---|
Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs.
Topics: Animals; Anti-Inflammatory Agents; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Coronavirus Infections; COVID-19; Drug Evaluation, Preclinical; Drug Repositioning; Humans; Niclosamide; Pandemics; Pneumonia, Viral; Pregnenediones; SARS-CoV-2; Vero Cells | 2020 |
Bazedoxifene-induced ROS promote mitochondrial dysfunction and enhance osimertinib sensitivity by inhibiting the p-STAT3/SOCS3 and KEAP1/NRF2 pathways in non-small cell lung cancer.
Topics: Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Kelch-Like ECH-Associated Protein 1; Lung Neoplasms; Mitochondria; NF-E2-Related Factor 2; Reactive Oxygen Species; Suppressor of Cytokine Signaling 3 Protein | 2023 |